search
Back to results

Primary Prevention of Hypertension in Obese Adolescents

Primary Purpose

Obesity, Pre-Hypertension, Hyperuricemia

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Allopurinol
Probenecid
Placebo
Sponsored by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

11 Years - 18 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Children between the ages of 11 and 18 body mass index greater than the 95th percentile for age Blood pressure between 75th and 95th percentile for age, gender and height percentile Exclusion Criteria: hypertension at the time of screening allergy to one of the study medications liver function abnormality (AST or ALT greater than twice the upper limit of normal for the laboratory) history of renal stones renal insufficiency (Schwartz formula calculated GFR less than 70ml per min per 1.73m2 BSA) positive urine pregnancy test diabetes organ transplant recipient currently treated with an angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), diuretic, other medications known to alter serum uric acid level lack of ability to comply with the study protocol

Sites / Locations

  • Texas Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Allopurinol

Probenecid

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Casual BP

Secondary Outcome Measures

24- hour Ambulatory BP
Systemic Vascular Resistance (measured by bioimpedance)

Full Information

First Posted
February 6, 2006
Last Updated
September 12, 2017
Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators
Baylor University
search

1. Study Identification

Unique Protocol Identification Number
NCT00288158
Brief Title
Primary Prevention of Hypertension in Obese Adolescents
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
September 2008 (Actual)
Primary Completion Date
January 2011 (Actual)
Study Completion Date
January 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators
Baylor University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to examine the consequences of lowering serum uric acid in pre-hypertensive, obese adolescents pathways involved with how uric acid mediated hypertension and renal disease. The specific aims are: Test the hypothesis that lowering uric acid will improve endothelial function. Test the hypothesis that lowering uric acid will reduce plasma renin activity and serum angiotensin II levels. Test the hypothesis that lowering uric acid will reduce markers of inflammation
Detailed Description
The trial will be a double blinded, placebo control trial of two uric acid lowering agents. The endpoints for this trial will be, endothelial function, systemic vascular resistance, plasma renin activity, MCP-1 and CRP. Upon recruitment and informed consent, children will undergo initial screening. This will include medical history, family history, dietary history, review of systems (questionnaire used and validated in pediatric hypertension clinic) and pediatric quality of life questionnaire. They will have a physical exam, casual and ambulatory blood pressure monitoring (see below) and screening laboratory analysis that will include CBC, electrolytes, BUN, Cr, Uric acid, AST, ALT and urinary micro-albumin to creatinine ratio. Children with serum uric acid less than 5.0mg per dl will be enrolled as controls and only have baseline studies at Screening and Visit 1. Children with serum uric acid equal to or greater than 5.0mg per dl will be randomized (in a one to one to one ratio) to receive placebo, allopurinol or probenecid. Study drug (or placebo) will be administered for 2 months. During the first week, subjects will take one tablet (placebo, 150mg allopurinol or 250mg probenecid) twice daily. At the end of one week subjects will be instructed to increase to 2 tablets (placebo, 300mg allopurinol or 500mg probenecid) twice daily. Data collection will occur during screening, after one and two months on the study drug and one month after completion of the study drug.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Pre-Hypertension, Hyperuricemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Allopurinol
Arm Type
Experimental
Arm Title
Probenecid
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Allopurinol
Intervention Type
Drug
Intervention Name(s)
Probenecid
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Casual BP
Time Frame
3 months
Secondary Outcome Measure Information:
Title
24- hour Ambulatory BP
Time Frame
3 months
Title
Systemic Vascular Resistance (measured by bioimpedance)
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
11 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Children between the ages of 11 and 18 body mass index greater than the 95th percentile for age Blood pressure between 75th and 95th percentile for age, gender and height percentile Exclusion Criteria: hypertension at the time of screening allergy to one of the study medications liver function abnormality (AST or ALT greater than twice the upper limit of normal for the laboratory) history of renal stones renal insufficiency (Schwartz formula calculated GFR less than 70ml per min per 1.73m2 BSA) positive urine pregnancy test diabetes organ transplant recipient currently treated with an angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), diuretic, other medications known to alter serum uric acid level lack of ability to comply with the study protocol
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel I Feig, MD, PhD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Texas Children's Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23006736
Citation
Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012 Nov;60(5):1148-56. doi: 10.1161/HYPERTENSIONAHA.112.196980. Epub 2012 Sep 24.
Results Reference
derived
PubMed Identifier
21849262
Citation
Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother. 2011 Oct;9(5):271-85. doi: 10.1016/j.amjopharm.2011.07.004. Epub 2011 Aug 17.
Results Reference
derived

Learn more about this trial

Primary Prevention of Hypertension in Obese Adolescents

We'll reach out to this number within 24 hrs